Bill Enright, CEO of Barinthus Biotherapeutics, has a track record of taking on leadership roles during tumultuous times. He recounts how he turned around challenges at Altimmune during the 2008 financial crisis. Joining Barinthus before the COVID-19 pandemic, he made pivotal decisions that laid the foundation for future success. The conversation dives into innovations in immunotherapy targeting hepatitis B and celiac disease, as well as the importance of recognizing strategic opportunities in the ever-evolving biotech landscape.